ArticleVaccines2024
Epidemiology of Pertussis After the COVID-19 Pandemic: Analysis of the Factors Involved in the Resurgence of the Disease in High-, Middle-, and Low-Income Countries.
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Impact of the COVID-19 pandemic on the global burden of pertussis: An analysis of trends and the emergence of an immunity gap.Human vaccines & immunotherapeutics · 2026Article
- Effectiveness of DTaP-IPV//PRP-T vaccine against pertussis among infants and toddlers in Zhejiang, China: a retrospective cohort study.Emerging microbes & infections · 2026Article
- Early detection of pertussis related activity by wastewater surveillance ofEmerging microbes & infections · 2026Article
- Review
- Clinical characteristics and risk factors for severe pertussis in infants aged less than 3 months.Translational pediatrics · 2026Article
- Article
- Laboratory diagnosis of pertussis: A survey on provincial public health laboratory methods.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- The Ongoing Challenge of Pertussis in Eastern and Northern Europe: Recommendations from the Global Pertussis Initiative.Infectious diseases and therapy · 2026Review
- How Were Functional Somatic Symptoms in Children Influenced by the COVID-19 Pandemic? A Retrospective Study of Children Admitted to a Tertiary Pediatric Emergency Hospital in Bucharest, Romania.Life (Basel, Switzerland) · 2026Article
- Pertussis resurgence after the COVID-19 pandemic in four Western Pacific Countries and the USA, highlighting the 2025 outbreak in Japan.Scientific reports · 2026Article
- Molecular surveillance of Bordetella pertussis during the 2024 outbreak in Southeast Brazil: allelic profiles and comparison to vaccine strain.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Article
- Pertussis-SARS-CoV-2 Co-infection in Infants at Mohammed VI University Hospital, Marrakech, Morocco.Cureus · 2026Article
- The AuTOMATIC trial: a multicentre digitally-automated, Bayesian, adaptive, parallel, factorial randomised controlled trial of SMS reminders for childhood vaccination.The Lancet regional health. Western Pacific · 2026Article
- Epidemiology, Clinical Microbiology and Antimicrobial Therapy: A Shared Effort Against Infectious Diseases.Antibiotics (Basel, Switzerland) · 2026Article
- Benchmarking the readability, quality, and educational suitability of large language models in communicating pertussis.Frontiers in public health · 2026Article
- Preliminary epidemiological and clinical profile of the 2024 pediatric pertussis outbreak: a retrospective analysis.Frontiers in pediatrics · 2026Article
- The 2024-2025 Pertussis outbreak in children in Chengdu: A large-scale retrospective cross-sectional study.PloS one · 2026Article
- Antibiotic Prescription Patterns in Poland in the Years 2019-2024 Based on Reimbursement Data from the National Healthcare Fund.Antibiotics (Basel, Switzerland) · 2025Article
- Innovative adjuvant strategies for next-generation pertussis vaccines.Human vaccines & immunotherapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pertussis is a highly contagious bacterial disease of the respiratory tract that can be prevented by vaccination. Before the COVID-19 pandemic, the vaccine coverage rate for the third dose of a DPT-containing vaccine was 86%, with large disparities among countries. Since 2022, many high-income countries have reported a resurgence of pertussis, especially in the European region, but the disease has also caused outbreaks in middle- and low-income countries, despite their less extensive disease surveillance capacities. This paper aims to review the incidence rates (IRs) of pertussis in high-, middle-, and low-income countries following the COVID-19 pandemic and to discuss the most relevant factors associated with the resurgence of the disease. The epidemiology of pertussis is highly variable and is influenced not only by the type of vaccine used but also by the specific characteristics of the disease, vaccine coverage rates, vaccination schedules, and the quality of surveillance. Since the cessation of COVID-19 measures, there have been significant pertussis outbreaks that could have been partially mitigated with higher coverage rates and more comprehensive pertussis vaccination throughout life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.